Alnylam Pharmaceuticals (ALNY) Competitors $458.92 +5.36 (+1.18%) Closing price 04:00 PM EasternExtended Trading$458.72 -0.21 (-0.04%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALNY vs. AMGN, GILD, VRTX, REGN, BIIB, UTHR, INCY, NBIX, EXEL, and BMRNShould you be buying Alnylam Pharmaceuticals stock or one of its competitors? The main competitors of Alnylam Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), Exelixis (EXEL), and BioMarin Pharmaceutical (BMRN). These companies are all part of the "biotechnology" industry. Alnylam Pharmaceuticals vs. Its Competitors Amgen Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Biogen United Therapeutics Incyte Neurocrine Biosciences Exelixis BioMarin Pharmaceutical Alnylam Pharmaceuticals (NASDAQ:ALNY) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings. Which has more volatility and risk, ALNY or AMGN? Alnylam Pharmaceuticals has a beta of 0.32, suggesting that its share price is 68% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.49, suggesting that its share price is 51% less volatile than the S&P 500. Do analysts rate ALNY or AMGN? Alnylam Pharmaceuticals presently has a consensus price target of $439.58, suggesting a potential downside of 4.21%. Amgen has a consensus price target of $304.43, suggesting a potential upside of 6.44%. Given Amgen's higher probable upside, analysts clearly believe Amgen is more favorable than Alnylam Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alnylam Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 24 Buy rating(s) 0 Strong Buy rating(s) 2.86Amgen 2 Sell rating(s) 12 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.24 Does the media prefer ALNY or AMGN? In the previous week, Amgen had 36 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 65 mentions for Amgen and 29 mentions for Alnylam Pharmaceuticals. Amgen's average media sentiment score of 1.57 beat Alnylam Pharmaceuticals' score of 0.84 indicating that Amgen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 12 Very Positive mention(s) 2 Positive mention(s) 10 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Amgen 60 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has better valuation & earnings, ALNY or AMGN? Amgen has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlnylam Pharmaceuticals$2.25B26.76-$278.16M-$2.47-185.80Amgen$33.42B4.61$4.09B$12.2323.39 Do institutionals & insiders hold more shares of ALNY or AMGN? 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 1.2% of Alnylam Pharmaceuticals shares are held by company insiders. Comparatively, 0.7% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is ALNY or AMGN more profitable? Amgen has a net margin of 18.96% compared to Alnylam Pharmaceuticals' net margin of -12.96%. Amgen's return on equity of 174.71% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Alnylam Pharmaceuticals-12.96% -273.52% -7.39% Amgen 18.96%174.71%13.12% SummaryAmgen beats Alnylam Pharmaceuticals on 11 of the 16 factors compared between the two stocks. Get Alnylam Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALNY vs. The Competition Export to ExcelMetricAlnylam PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$59.45B$3.16B$5.80B$10.46BDividend YieldN/A2.36%5.61%4.57%P/E Ratio-185.8021.03348.5626.86Price / Sales26.76447.99549.90125.65Price / CashN/A44.8326.0131.15Price / Book882.549.8315.536.50Net Income-$278.16M-$52.82M$3.29B$271.25M7 Day Performance-0.48%3.47%200.87%3.69%1 Month Performance1.00%5.35%184.38%8.07%1 Year Performance67.56%13.26%325.51%29.65% Alnylam Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALNYAlnylam Pharmaceuticals3.8578 of 5 stars$458.92+1.2%$439.58-4.2%+65.6%$59.45B$2.25B-185.802,230Analyst ForecastAMGNAmgen4.6052 of 5 stars$274.40-0.7%$304.43+10.9%-15.4%$147.73B$34.92B22.4428,000Positive NewsGILDGilead Sciences4.9577 of 5 stars$112.54-1.8%$115.39+2.5%+35.9%$139.64B$28.75B22.4217,600Positive NewsVRTXVertex Pharmaceuticals4.9103 of 5 stars$393.21-0.3%$496.05+26.2%-17.6%$100.82B$11.02B28.116,100Positive NewsAnalyst RevisionREGNRegeneron Pharmaceuticals4.7914 of 5 stars$572.59+2.2%$817.67+42.8%-48.3%$60.69B$14.21B14.4315,106Positive NewsBIIBBiogen4.6727 of 5 stars$143.32-1.1%$181.65+26.7%-28.5%$21.01B$10.00B13.707,605Positive NewsAnalyst DowngradeUTHRUnited Therapeutics4.6475 of 5 stars$403.11-0.5%$438.85+8.9%+18.3%$18.18B$3.08B15.731,305Insider TradeINCYIncyte4.7647 of 5 stars$83.14+0.0%$82.53-0.7%+31.6%$16.24B$4.24B18.902,617Positive NewsAnalyst ForecastNBIXNeurocrine Biosciences4.4666 of 5 stars$140.44-1.0%$160.00+13.9%+22.7%$13.93B$2.51B41.551,800Positive NewsAnalyst ForecastEXELExelixis4.6779 of 5 stars$39.01-0.4%$44.06+12.9%+51.8%$10.50B$2.17B18.751,147Positive NewsBMRNBioMarin Pharmaceutical4.9651 of 5 stars$53.14-1.8%$92.04+73.2%-23.1%$10.20B$2.85B15.773,040Positive News Related Companies and Tools Related Companies Amgen Alternatives Gilead Sciences Alternatives Vertex Pharmaceuticals Alternatives Regeneron Pharmaceuticals Alternatives Biogen Alternatives United Therapeutics Alternatives Incyte Alternatives Neurocrine Biosciences Alternatives Exelixis Alternatives BioMarin Pharmaceutical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALNY) was last updated on 9/22/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredPrepare for the “Mar-a-Lago Accord” Money ShockWhy Are Wall Street Insiders Moving Their Money to This ONE Asset? Something far more consequential for you...Stansberry Research | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredThe next AI Hype Spike is days away — don’t miss itOn this date, AI could trigger the kind of predictable surge that's already paid out 61%… 158%… and even 382% ...Brownstone Research | SponsoredTrump Devises the Death of the IRS ☠️Trump has just signed an executive order creating America's first-ever National Investment Fund — a game-chang...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALNY Stock Alerts